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doi:10.1Objective: Our objective was to examine whether preoperative non–dialysis-dependent renal dysfunction is as-
sociated with operative mortality or morbidity in isolated valve surgery.
Methods: We reviewed consecutive patients undergoing isolated aortic (n ¼ 2132) or mitral valve (n ¼ 1664)
surgery, between 1996 and 2009. Preoperative renal dysfunction was defined as preoperative estimated glomer-
ular filtration rate<60 mL/min without dialysis. Propensity score 1:1 matched samples were created, one for
aortic (n ¼ 626) and one for mitral (n ¼ 526) valve surgery.
Results: The mean age was 70 9 and 65 10 years for the aortic and mitral groups, respectively. In the aortic
cohort, patients with preoperative renal dysfunction had greater need for inotropes (39% vs 29%; P ¼ .009),
length of intensive care unit stay (27 vs 25 hours; P ¼ .006), and duration of mechanical ventilation (8.2 vs
6.6 hours; P< .001). Operative mortality was 3.2% in the group with preoperative renal dysfunction and
2.2% in the group without preoperative renal dysfunction (P ¼ .5). In the mitral cohort, patients with preoper-
ative renal dysfunction had greater need for inotropes (47% vs 36%; P¼ .013), length of intensive care unit stay
(40 vs 26 hours; P ¼ .01), and duration of mechanical ventilation (7.2 vs 6.5 hours; P ¼ .004). Operative mor-
tality was 0% and 2.7% in the groups without and with preoperative renal dysfunction, respectively (P¼ .015).
Conclusions: Preoperative renal dysfunction is associated with higher morbidity in both cohorts, and patients
undergoing mitral valve surgery also experienced higher mortality. The impact of non–dialysis-dependent
preoperative renal dysfunction appears to be more pronounced in patients undergoing mitral valve surgery,
potentially owing to their relative intolerance to volume overload. (J Thorac Cardiovasc Surg 2011;142:155-61)P
MChronic kidney disease is a significant public health problem
whose prevalence is progressively increasing in the world,
particularly in developed countries.1,2 Chronic kidney
disease is a widely known risk factor for the development
and progression of cardiovascular diseases and currently
affects approximately 2 million Canadians, which accounts
for 6% of the total population in Canada.3-5 As
a consequence, preoperative renal dysfunction (PRD) is
prevalent in patients undergoing cardiovascular surgery. In
a recent multicenter Canadian cohort study, approximately
30% of the patients undergoing cardiovascular surgery had
an estimated preoperative glomerular filtration rate (GFR)
less than 60 mL/min.6
The implications of kidney failure with chronic renal re-
placement therapy (chronic kidney disease stage 5) on car-
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The Journal of Thoracic and Cathe influence of the preoperative renal function on the
development of postoperative acute renal failure and on
operative mortality (OM) after cardiac surgery has been
documented.10 In addition, multiple studies have shown
increased mortality and morbidity in patients undergoing
coronary artery bypass graft (CABG) surgery with non–
dialysis-dependent chronic renal failure.11-14 PRD has
also been found to be a significant predictor of late
mortality in CABG surgery.15 However, in isolated valve
surgery, the association between PRD and mortality and
morbidity has not been as well defined. We also hypothe-
sized that the impact of PRDmay be different in patients un-
dergoing aortic valve surgery (AVS), primarily for pressure
overload physiology, versus mitral valve surgery (MVS) for
predominantly volume overload pathology.
METHODS
Ethical Requirements and Study Setting
The University of Toronto Research Ethics Board approved this study,
and given the observational study design, an individual patient consent
was waived. The study setting is the Toronto General Hospital in Toronto,
Ontario, Canada.
Study Design and Participants
From a cohort of patients who underwent cardiac surgery at the Toronto
General Hospital between 1996 and 2009, we reviewed consecutive
patients undergoing isolated aortic (AVS: n ¼ 2132) or mitral valve
(MVS: n¼ 1664) surgery. All datawere prospective collected by a full-timerdiovascular Surgery c Volume 142, Number 1 155
Abbreviations and Acronyms
AVS ¼ aortic valve surgery
BSA ¼ body surface area
CABG ¼ coronary artery bypass graft
GFR ¼ glomerular filtration rate
IQR ¼ interquartile range
LCOS ¼ low cardiac output syndrome
MVS ¼ mitral valve surgery
OM ¼ operative mortality
PRD ¼ preoperative renal dysfunction
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Mprofessional research team. The quality of the data was assessed by random
interrogation and the final edition stored in a computerized database after
external validation.
PRD Classification
PRD was defined as preoperative estimated GFR less than 60 mL/min
without the need for dialysis using the Cockcroft–Gault formula.9 The
selection of this formula was based on its worldwide use and extensive
temporal and external validation since its publication in 1976. In addition,
the discrimination ability for OM after cardiovascular surgery using the
Cockcroft–Gault formula has been reported as similar in comparison
with a new method, the Modification of Diet in Renal Disease equation.9,16
Covariables
The following preoperative variables were included: sex, age, body sur-
face area (BSA), family history of cardiac disease, and associated comor-
bidities including, diabetes mellitus, hypertension, hyperlipidemia, chronic
obstructive pulmonary disease, previous stroke or transitory ischemic at-
tack, peripheral vascular disease, carotid disease, previous cardiac opera-
tions, previous CABG surgery, active endocarditis, previous or active
endocarditis, New York Heart Association functional class, angina, urgent
or emergency surgery, congestive heart failure, left ventricular ejection
fraction, smoking, preoperative myocardial infarction, and pre-existing
atrial fibrillation. Clinical variables were defined using standard opera-
tional definitions.6,10,11,13
The following intraoperative variables were collected: cardiopulmonary
bypass time, aortic crossclamp time, valvular replacement, valvular repair,
annular enlargement in AVS, or annular reconstruction in MVS.
Outcomes
The primary outcome was OM and was defined as any death during the
index hospital admission or during the first 30 postoperative days. The fol-
lowing secondary outcome variables were collected: reoperation for any
cause, perioperative myocardial infarction, low cardiac output syndrome
(LCOS), perioperative stroke, renal failure (defined as need for renal
replacement therapy), sternal wound infection, sepsis, pulmonary compli-
cation, atrial fibrillation, use of intra-aortic balloon pump, use of inotropes,
length of mechanical ventilation, length of stay in the intensive care unit,
and postoperative length of stay.
Statistical Analysis
Categorical variables are reported as number and percentages. Contin-
uous variables are expressed as mean and standard deviation or median
and interquartile range (IQR). All statistical analyses were performed
with the SAS 9.1 software (SAS Institute, Inc, Cary, NC). Statistical anal-
ysis was performed using the c2 test or Fisher exact test for categorical
variables and t tests or Kruskal–Wallis equality-of-populations rank test156 The Journal of Thoracic and Cardiovascular Surgfor continuous variables where appropriate. Propensity score 1:1 matched
samples were created independently; one for AVS and one for MVS. The
propensity score methodology was in accordance with Rosenbaum and as-
sociates17,18 and the current state of the art literature.19-21 Technical aspects
are presented in Appendices 1–3.
Considering the quality of the database and the minimal percentage of
missing data (data not reported), no multiple imputation techniques were
considered. Also, no adjustment for multiplicity was considered in the
analyses. Finally, all the analyses were performed independently for the
AVS and MVS matched sample groups.
RESULTS
Characteristics of the Propensity Score–Matched
Samples
The match selected 626 and 526 patients in the AVS and
MVS samples who were well matched with a mean age of
70 9 and 65 10 years, respectively. The clinical charac-
teristics of the matched samples are presented in Tables 1
(AVS) and 2 (MVS). As expected with the propensity score
matching technique, there were no significant differences
between the PRD and non-PRD patients in either cohort
of valve surgery. The only exception was the BSA, which
was smaller in the PRD groups (AVS: 1.75  0.21 vs 1.94
 0.20 m2, P< .001; MVS: 1.70  0.19 vs 1.88  0.23
m2, P<.001) of both cohorts. The type of valvular lesion
and operative techniques were not statistically different be-
tween groups in either cohort (Appendix 4). The type of val-
vular lesion in both samples is presented in Appendix 4.
Finally, the perioperative and outcome variables for AVS
and MVS are presented in Tables 3 and 4, respectively.
Primary Outcomes of the Propensity-Matched
Samples
In the AVS cohort, OM was similar (2.2% vs 3.2%;
P ¼ .5) in the non-PRD and PRD groups. In contrast, in
the MVS cohort OM was lower in the non-PRD group
(0% vs 2.7%; P ¼ .015) (Figure 1). The timing and causes
of OM in the MVS cohort are presented in Appendix 5.
Secondary Outcomes in the AVS Group
In the AVS group, patients with PRD had greater need for
inotropes (39% vs 29%; P¼ .009), duration of mechanical
ventilation (8 hours [IQR ¼ 9 hours] vs 7 hours [IQR ¼ 5
hours]; P< .001) and length of intensive care unit stay
(27 hours [IQR ¼ 46 hours] vs 25 hours [IQR ¼ 27 hours];
P ¼ .006). There were no significant differences between
groups in need for reoperation, perioperative myocardial in-
farction, LCOS, perioperative stroke, renal failure, sternal
wound infection, sepsis, pulmonary complication, atrial
fibrillation, use of intra-aortic balloon pump, and postoper-
ative length of stay (Table 3).
Secondary Outcomes in the MVS Group
In the MVS group, patients with PRD had greater
need for inotropes (47% vs 36%; P ¼ .013), duration ofery c July 2011
TABLE 1. Clinical characteristics of the matched aortic valve surgery
groups (n ¼ 313/group)
Variable Non-PRD PRD P value
Male sex 56.9% 178 53.0% 166 .335z
Age (y): mean (SD) 70.5 (8.26) 70.4 (9.39) .910*
BSA (m2): mean (SD) 1.94 (0.20) 1.75 (0.21) <.001*,y
Family history 38.5% 120 33.0% 103 .156z
NYHA III or IV 71.6% 224 70.0% 219 .593z
CHF 51.1% 160 49.8% 156 .749z
Angina 1.3% 4 1.3% 4 1.0x
Urgent/emergency 4.5% 14 6.1% 19 .789z
Redo CABG 6.1% 19 3.5% 11 .134z
Any redo 16.0% 50 13.7% 43 .432z
COPD 5.1% 16 7.0% 22 .315z
LVEF<40% 11.8% 37 16.9% 53 .168z
Diabetes 13.4% 42 13.4% 42 1.0z
Hypertension 49.8% 156 49.8% 156 1.0z
Hyperlipidemia 42.2% 132 39.6% 124 .516z
PVD 8.9% 28 8.3% 26 .776z
Active endocarditis 1.9% 6 3.2% 10 .391z
Any endocarditis 5.8% 18 5.1% 16 .724z
Preop. MI 1.6% 5 1.3% 4 .737x
Stroke/TIA 9.6% 30 8.9% 28 .783z
AF 9.3% 29 8.9% 28 .890z
PRD, Preoperative renal dysfunction; SD, standard deviation; BSA, body surface area;
NYHA,NewYork Heart Association;CHF, congestive heart failure; Redo CABG, pre-
vious coronary artery bypass graft surgery; Any redo, previous cardiac surgery;
COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection frac-
tion; PVD, peripheral vascular disease; Preop. MI, preoperative myocardial infarc-
tion; TIA, transitory ischemic attack; AF, atrial fibrillation. *Two-sample t test.
yP<.05. zc2 test. xFisher exact test.
TABLE 2. Clinical characteristics of thematchedmitral valve surgery
groups (n ¼ 263/group)
Variable Non-PRD PRD P value
Male sex 39.9% 105 39.2% 103 .858z
Age (y): mean (SD) 64.6 (9.83) 64.4 (11.05) .878*
BSA (m2): mean (SD) 1.88 (0.23) 1.70 (0.19) <.001*,y
Family history 40.1% 105 34.0% 89 .148z
NYHA III or IV 70.0% 184 71.5% 188 .702z
CHF 65.0% 171 62.4% 164 .526z
Angina 6.1% 16 7.6% 20 .499z
Urgent/emergency 2.3% 6 4.2% 11 .218z
Redo CABG 4.2% 11 3.4% 9 .648z
Any redo 16.7% 44 20.2% 53 .312z
COPD 4.2% 11 3.4% 9 .649z
LVEF<40% 6.5% 17 9.1% 24 .255z
Diabetes 11.4% 30 8.0% 21 .185z
Hypertension 38.0% 100 32.7% 86 .202z
Hyperlipidemia 29.7% 78 26.2% 69 .382z
PVD 2.3% 6 2.3% 6 1.0z
Active endocarditis 2.7% 7 4.9% 13 .171z
Any endocarditis 8.0% 21 9.9% 26 .445z
Preop MI 0.8% 2 0.8% 2 1.0x
Stroke/TIA 8.8% 23 12.2% 32 .200z
AF 35.0% 92 33.5% 88 .713z
PRD, Preoperative renal dysfunction; SD, standard deviation; BSA, body surface area;
NYHA,NewYork Heart Association;CHF, congestive heart failure; Redo CABG, pre-
vious coronary artery bypass graft surgery; Any redo, previous cardiac surgery;
COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection frac-
tion;PVD, peripheral vascular disease; PreopMI, preoperativemyocardial infarction;
TIA, transitory ischemic attack; AF, Atrial fibrillation. *Two-sample t test. yP<.05.
zc2 test. xFisher exact test.
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Mmechanical ventilation (7 hours [IQR ¼ 7 hours] vs 6 hours
[IQR¼ 5 hours];P¼ .004), and length of intensive care unit
stay (40 hours [IQR ¼ 47 hours] vs 26 hours [IQR ¼ 27
hours]; P ¼ .011). As in the AVS cohort, there were no sig-
nificant differences between groups in need for reoperation,
perioperative myocardial infarction, LCOS, perioperative
stroke, renal failure, sternal wound infection, sepsis, pulmo-
nary complication, atrial fibrillation, use of intra-aortic
balloon pump, or postoperative length of stay (Table 4).
DISCUSSION
In patients undergoing isolated valve surgery, we identi-
fied PRD to be associated with perioperative mortality after
MVS but not AVS. However, the presence of PRD led to
clinically significant morbidity in both cohorts.
Anderson and coworkers22 in 2000 reported mild renal
insufficiency as an independent risk factor for adverse out-
comes after cardiac valve surgery. Their sample, which in-
cluded 834 patients undergoing valvular surgery with or
without concomitant CABG from 14 Veterans’ Affairs
Medical Centers between 1992 and 1996, was stratified as
normal renal function (serum creatinine < 1.5 mg/dL,
n ¼ 637), mild-to-moderate renal failure (serum creatinine
between 1.5 and 3.0 mg/dL, n ¼ 183), and advanced renal
failure (serum creatinine>3.0 mg/dL, n ¼ 14). In a multi-The Journal of Thoracic and Cavariable logistic regression model, mild-to-moderate renal
failure was associated with OM (P ¼ .001) and postopera-
tive morbidity. However, only 73 patients in their study
displayed mild-to-moderate renal failure. In addition to
a highly selected population of veterans, they did not inde-
pendently examine the effects of renal function on AVS and
MVS.
Abramov and associates23 in 2003 reported preoperative
renal dysfunction as an independent predictor of mortality
and morbidity in a sample of 2214 patients, predominatly
isolated CABG (82%) with only 5% and 4% undergoing
AVS and MVS, respectively. Preoperative creatinine clear-
ance less than 0.84 mL $ s1 $ m2 was correlated with an
exponential increase in a composite outcome of periopera-
tive mortality, myocardial infarction, LCOS, and cerebro-
vascular accident. Again, their study had a very small
sample of valve patients and did not report the results of
AVS and MVS separately. Our study focuses selectively
on isolated valve surgery and, with a relatively larger sam-
ple size, we were able to demonstrate a clear difference be-
tween aortic and mitral populations. Owing to the fact that
we intentionally excluded patients requiring preoperative
renal replacement therapy, we did not stratify patients
according to the severity of renal dysfunction as per Ander-
son,22 Filsoufi,24 and their associates. Similar to our resultsrdiovascular Surgery c Volume 142, Number 1 157
TABLE 3. Perioperative data in the matched aortic valve surgery
groups
Variable
Non-PRD
(n ¼ 313)
PRD
(n ¼ 313)
P
value
CPB time (min): mean (SD) 101 (40.1) 96 (35.1) .100*
Crossclamp time (min): mean (SD) 77 (32.5) 73 (27.5) .092*
Aortic valve replacement: n (%) 290 (92.7%) 297 (94.9%) .247z
Aortic annulus enlargement: n (%) 62 (19.8%) 50 (16.0%) .204z
Reoperation: n (%) 28 (8.9%) 35 (11.2%) .352z
Postoperative bleeding: n (%) 22 (7.0%) 25 (8.0%) .649z
Postoperative tamponade: n (%) 3 (1.0%) 5 (1.6%) .725k
Mortality: n (%) 7 (2.2%) 10 (3.2%) .461z
Ventilation time (h): median (IQR) 6.6 (5.0) 8.2 (9.4) <.001y,x
LICU (h): median (IQR) 24.8 (26.9) 27.4 (46.1) .006y,x
Postoperative stay (d): median
(IQR)
7 (4) 8 (5) .163x
LCOS: n (%) 7 (2.2) 10 (3.2) .457
Myocardial Infarction: n (%) 3 (1.0%) 3 (1.0%) 1.0k
Sternal wound infection: n (%) 6 (1.9%) 3 (1.0%) .505k
Sepsis: n (%) 3 (1.0%) 5 (1.6%) .725k
Stroke (%) 8 (2.6%) 7 (2.2%) .794z
Pulmonary complication: n (%) 29 (9.3%) 39 (12.5%) .199z
Renal failure: n (%) 3 (1.0%) 7 (2.2%) .340k
Atrial fibrillation: n (%) 112 (35.8%) 95 (30.4%) .149z
IABP: n (%) 4 (1.3%) 7 (2.2%) .545k
Use of inotropes: n (%) 91 (29.1%) 122 (39.0%) .009y,z
PRD, Preoperative renal dysfunction; CPB, cardiopulmonary bypass; SD, standard
deviation; IQR, interquartile range; LICU, length of intensive care unit stay; LCOS,
low cardiac output syndrome; IABP, intra-aortic balloon pump. *Two-sample t test.
yP<.05. zc2 test. xKruskal–Wallis equality-of-populations rank test. kFisher exact
test.
TABLE 4. Perioperative data in the matched mitral valve surgery
groups
Variable
Non-PRD
n ¼ 263
PRD
n ¼ 263
P
value
CPB time (min): mean (SD) 89.3 (38.4) 92 (37.1) .497*
Crossclamp time (min):
mean (SD)
68 (29.5) 70 (34.9) .379*
Mitral valve replacement: n (%) 127 (48.3%) 148 (55.3%) .067z
Mitral annulus reconstruction:
n (%)
9 (3.4%) 15 (5.7%) .206z
Reoperation: n (%) 14 (5.3%) 17 (6.5%) .579z
Postoperative bleeding: n (%) 8 (3.0%) 14 (5.3%) .191z
Postoperative tamponade: n (%) 2 (0.8%) 3 (1.1%) 1.0k
Mortality: n (%) 0 (0%) 7 (2.7%) .015y,k
Ventilation time (h): median (IQR) 6.5 (5.4) 7.2 (6.6) .004y,x
LICU (h): median (IQR) 26.2 (26.5) 39.8 (47.3) .011y,x
Postoperative stay (d): median
(IQR)
7 (5) 8 (4) .310x
LCOS: n (%) 3 (1.1) 9 (3.4) .141k
Myocardial infarction: n (%) 2 (0.8%) 2 (0.8%) 1.0k
Sternal wound infection: n (%) 1 (0.4%) 1 (0.4%) 1.0k
Sepsis: n (%) 2 (0.8%) 4 (1.5%) .686k
Stroke: n (%) 1 (0.4%) 6 (2.3%) .123k
Pulmonary complication: n (%) 24 (9.1%) 32 (12.2%) .258z
Renal failure: n (%) 1 (0.4%) 6 (2.3%) .061k
Atrial fibrillation: n (%) 67 (26.3%) 71 (27.0%) .844z
IABP: n (%) 2 (0.8%) 6 (2.3%) .285k
Use of inotropes: n (%) 95 (36.1%) 123 (46.8%) .013y,z
PRD, Preoperative renal dysfunction; CPB, cardiopulmonary bypass; SD, standard
deviation; IQR, interquartile range; LICU, length of intensive care unit stay; LCOS,
low cardiac output syndrome; IABP, intra-aortic balloon pump. *Two-sample t test.
yP<.05. zc2 test. xKruskal–Wallis equality-of-populations rank test. kFisher exact
test.
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Min AVS, Iba~nez and coworkers25 reported in a sample of 681
valvular patients with or without concomitant CABG, no
difference in OM between patients with (n ¼ 207) or with-
out (n ¼ 474) PRD (3.4% vs 2.3%; P ¼ .43). The main
finding of their study was that PRD patients had a higher in-
cidence of reoperation (6.8% vs 2.3%; P<.001), red blood
cell transfusions, longer ventilation time, and hospital stay.
Unfortunately, their study had a severe demographic imbal-
ance between groups and they did not use a propensity score
analysis to adjust risk. We did not investigate total transfu-
sion requirements, but we also found differences in ventila-
tion time and postoperative length of stay.
Howell and associates26 reported that mild renal dysfunc-
tion, defined as an estimated GFR less than 60/mL per
1.73 m2, was a predictor of early and late mortality. These
authors stratified renal risk according to estimated GFR
and found renal dysfunction in 74% of their 7621 patient
cohort. Their sample included 1756 (23% of the entire sur-
gical cohort) patients with valve surgery. The in-hospital
mortality was 3.2% and directly correlated to the degree
of renal dysfunction. Multivariate analysis demonstrated
a stronger correlation in patients undergoing isolated
CABG (odds ratio ¼ 12.2), but a mortality effect persisted
in patients undergoing valvular surgery. Unfortunately, this158 The Journal of Thoracic and Cardiovascular Surglarge study did not analyze the differential effect of renal
dysfunction in patients undergoing AVS versus MVS. Our
results show a clear difference between AVS and MVS,
with PRD predicting mortality only in the MVS group.
Also, the magnitude of the effect in MVS in our study
(odds ratio ¼ 10.4) is greater than Howell and colleagues26
observed even in their group with the most severe renal
dysfunction undergoing isolated valve surgery (odds
ratio ¼ 6.97).
Similarly, Diez and colleagues27 reported mild renal dys-
function, defined as an estimated GFR less than 60/mL per
1.73 m2, as a predictor of in-hospital mortality. Their sam-
ple included 994 patients with isolated or combined valve
and CABG surgery. However, isolated aortic valve or mitral
valve replacement represented only 307 and 115 patients,
respectively. Estimated GFR predicted mortality and post-
operative acute renal failure; however, the independent as-
sociation based on valve site was not reported. Therefore,
a direct comparison with our results is not possible.
Interestingly, our study failed to demonstrate a correla-
tion of PRD and postoperative renal failure, defined as
the need for renal replacement therapy. Likely, this is due
to the fact that only 17 patients (AVS, n ¼ 10; MVS,ery c July 2011
FIGURE 1. Operative mortality in the mitral valve surgery and aortic
valve surgery propensity score matched samples. AVS, Aortic valve sur-
gery; MVS, mitral valve surgery; PRD, perioperative renal dysfunction
(non–dialysis dependent); non-PRD, no perioperative renal dysfunction.
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Mn ¼ 7) in the entire cohort required dialysis. The differen-
tial effect of PRD on AVS and MVS was a surprising find-
ing and, to our knowledge, has not been previously
described. We hypothesize that patients undergoing MVS
are less tolerant of postoperative fluid retention owing to
their volume overload physiology and thus suffer to
a greater proportion from a similar degree of renal dysfunc-
tion. Alternatively, patients undergoing AVS were more
likely to suffer from aortic stenosis and thus their renal dys-
function may comprise a more ‘‘prerenal’’ component than
those patients undergoing MVS. However, our data do not
support any association between type of valve disease, as
a surrogate of intracardiac pressure or volume overload
physiology, and outcomes in this study (data not provided).
In summary, our results are in agreement with previous re-
ports in this area but definitely expand and clarify the rela-
tionship between PRD and OM in isolated valve surgery.
The novel aspects of our study include the use of propen-
sity score matching to balance demographic differences
and the consideration of the intrinsic differences between
aortic and mitral valve disease.
There are several limitations to our study. First, despite
the use of a standard propensity matched sampling tech-
nique, the distribution of BSA is unequal. However, the
BSA distributions are unlikely to explain the results, partic-
ularly inMVS, where the concept of prosthesis–patient mis-
match is less established.28,29 Second, more aggressive
diuretic therapy may be necessary in advanced cases of
valve disease, which can exacerbate PRD. Despite the use
of propensity scores, we were unable to document actual
diuretic therapy in each patient. Third, our estimation of
GFR was performed with the Cockcroft–Gault formula
and not with more recent equations such as the
Modification of Diet in Renal Disease, which is the basisThe Journal of Thoracic and Cafor the current chronic kidney disease classification.
However, all equations for estimation of GFR are by
definition only an approximation of the real physiologic
GFR. Fourth, we did not explore as covariates the use of
aprotinin, colloids, or blood products. Fifth, we did not
differentiate between acute and chronic valvular disease,
nor did we assess the chronicity of PRD. However,
surgery was performed in an urgent or emergency fashion
in less than 7% of these cases. Therefore, the vast
majority of these patients had chronic valvular disease.
Sixth, the PRD MVS group has a relatively higher
proportion of mitral valve replacement than did the non-
PRDMVS group, which is not statistically significant. Con-
sidering that we did not performed statistical adjustment for
multiple analysis, we do not believe this is a statistical type I
error and consequently not a real bias. Seventh, the time be-
tween preoperative angiography and the determination of
estimated GFR was also variable, but is likely equally dis-
tributed among all groups. Finally, the number of events
for our main outcome, OM, is small and therefore the gen-
eralizability of our conclusions may be limited.CONCLUSIONS
In conclusion, our results demonstrate that PRD is asso-
ciated with OM in MVS but not in AVS. In addition, PRD is
associated with clinically significant morbidity in patients
undergoing MVS, with a smaller impact in AVS.
This is the first study to distinguish the effects of PRD be-
tween AVS and MVS. We concede that this is an observa-
tional study, limited to perioperative outcomes. The
potential differential effects of PRD on long-term clinical
outcomes should be investigated in a similar manner. We
hypothesize that renal function may improve after AVS
for aortic stenosis, but may worsen after MVS for valvular
insufficiency.References
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APPENDIX 4. Type of valvular lesion
Variable Non-PRD PRD P value
Aortic valve surgery
Valve disease n n .515*
Stenosis 61.7% 192 59.9% 185
Regurgitation 19.9% 62 24.3% 75
Mixed 17.0% 53 15.2% 47
None 1.3% 4 0.7% 2
Mitral valve surgery
Valve disease n n .873*
Stenosis 10.5% 27 9.7% 25
Regurgitation 77.0% 198 75.7% 196
Mixed 12.1% 31 14.3% 37
None 0.4% 1 0.4% 1
PRD, Preoperative renal dysfunction. *Fisher exact test.
APPENDIX 5. Clinical data in patients with perioperative death from the matched mitral valve surgery groups by patient
Patient PRD status Age (y) Year CHD MVR MAR Redo Time to death (mo) Cause of death
1 Yes 23 1996 No Yes Yes No 3 Sepsis (IE)
2 Yes 65 1998 No Yes No Yes 172 MOF
3 Yes 65 1999 No Yes No Yes 3 MOF
4 Yes 47 2001 No Yes No No 0 OR death
5 Yes 73 2001 No Yes Yes Yes 21 CVA
6 Yes 71 2005 No Yes Yes No 0 OR death
7 Yes 34 2009 Yes No No No 2 Heart/renal failure
PRD, Preoperative renal dysfunction; CHD, congenital heart disease; MVR, mitral valve replacement; MAR, mitral annulus reconstruction; IE, infective endocarditis;
MOF, multiorgan failure; OR, operating room; CVA, cerebrovascular accident.
APPENDIX 2. Mirrored histogram of distribution of the propensity
scores for unmatched and matched aortic valve surgery samples. AVS,Aor-
tic valve surgery; PRD, perioperative renal dysfunction (non–dialysis de-
pendent); non-PRD, no perioperative renal dysfunction.
APPENDIX 3. Mirrored histogram of distribution of the propensity
scores for unmatched and matched mitral valve surgery samples.MVS,mi-
tral valve surgery; PRD, perioperative renal dysfunction (non–dialysis de-
pendent); non-PRD, no perioperative renal dysfunction.
Garrido-Olivares et al Perioperative Management
The Journal of Thoracic and Cardiovascular Surgery c Volume 142, Number 1 161
P
M
